Overview

Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites

Status:
Completed
Trial end date:
2002-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effects of age on the pharmacokinetic profile of BIA 2-093 and its active metabolites.
Phase:
Phase 1
Details
Lead Sponsor:
Bial - Portela C S.A.
Treatments:
Eslicarbazepine acetate